SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.63+2.5%12:56 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sam Citron who wrote (7365)11/22/2002 9:21:33 AM
From: Biomaven  Read Replies (1) of 52153
 
Sam,

I think this is primarily a vote of confidence in MEDI's Flumist, with Wyeth's view that Flumist will rapidly take the market for flu vaccines once it is approved. Flumist not only does not involve a shot, but appears to have better efficacy in protecting against strains similar but not identical to those included in the vaccine.

Judging from this link, Wyeth's vaccine contains thimerosal, and maybe this had something to do with them dropping it as well given the current climate:

cdc.gov

Technically it's not that hard to make a vaccine without thimerosal, but of course you still have to jump through some regulatory hoops in order to sell a reformulated product. MEDI's technology isn't of any relevance that I am aware of in reformulating traditional vaccines without thimerosal.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News